# EpiAxis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epiaxis-therapeutics-pty

- Industry: Healthcare Specialists
- Headquarters: Canberra, Australia
- Website: www.epiaxistherapeutics.com
- Total disclosed funding: $1.7M
- Latest round: Series A (Apr 30, 2019)
- Investors on record: 2

## About

EpiAxis Therapeutics is focused on developing innovative epigenetic solutions for cancer treatment, offering proprietary therapies and diagnostic tools aimed at enhancing personalized medicine.EpiAxis Therapeutics Pty Ltd specializes in epigenetic research and therapies, with its headquarters located in Canberra, Australia. The company was founded by CEO Jeremy Chrisp, who has a background in advancing biotech initiatives. In January 2020, EpiAxis raised AUD 2.56 million through a venture funding round from investors including VentureCrowd, Proto Investment Partners, and ANU Connect Ventures, bringing the total amount raised to AUD 2.56 million and a current company valuation of AUD 11.41 million.EpiAxis Therapeutics specializes in innovative solutions in the field of epigenetics, particularly targeting cancer treatment and research. Their core offerings revolve around proprietary therapies and diagnostic tools designed to modify epigenetic markers, thereby influencing gene expression and cancer progression. These products aim to address the urgent need for more effective cancer treatments by providing personalized medicine approaches, which cater to the unique genetic makeup of individual patients. Their client base primarily includes research institutions, hospitals, and biotechnology firms engaged in cancer research and treatment across various geographical markets, including North America, Europe, and select regions in Asia. EpiAxis Therapeutics focuses on refining and enhancing cancer therapies, which are released into clinical settings and research environments to support oncologists and researchers in their work.EpiAxis Therapeutics generates revenue through a combination of strategic partnerships, B2B collaborations, and direct service offerings for clinical trials. The company’s revenue structure involves subscription-based models for access to their proprietary software and diagnostic tools, as well as transactional agreements for their therapeutic products, which may include licensing arrangements with pharmaceutical companies. Specific revenue streams may be derived from collaborations with research institutions for joint studies or clinical trials that leverage their epigenetic technologies. The flagship products of EpiAxis Therapeutics are designed to integrate seamlessly into existing cancer treatment protocols, facilitating a smoother transition for healthcare providers and ensuring that their offerings meet the needs of oncologists and patients.EpiAxis Therapeutics plans to leverage the AUD 2.56 million raised in January 2020 to support the development of new epigenetic therapies and expand its market presence. The company is focused on launching several new products aimed at enhancing treatment outcomes for cancer patients, with specific timelines to be announced as development progresses. EpiAxis is targeting expansion into additional markets across Europe and Asia by 2023, aiming to establish collaborations with oncologists and research institutions in these regions to facilitate the adoption of their innovative solutions.

## Funding rounds

- Series A, Apr 30, 2019, $1.2M — ANU Connect Ventures
- Seed, Jan 19, 2016, $0.5M — ANU Connect Ventures, University of Canberra Accomodation

## Investors

- ANU Connect Ventures (https://capitalatlas.ai/funds/anu-connect-ventures) — Seed, Series A
- University of Canberra Accomodation — Seed